Mylocar 60Mg Dry Vial Of 1 Powder For Injection

• Relapsed multiple myeloma: The condition has returned after earlier treatment; carfilzomib may slow abnormal plasma-cell growth as part of specialist care.
• Treatment-resistant multiple myeloma: The condition has not responded adequately to previous treatment; carfilzomib offers another medically supervised treatment option.
• Combination treatment: Carfilzomib may be given with medicines such as dexamethasone or lenalidomide to improve disease control in adults with relapsed or treatment-resistant disease.

• Fatigue: Carfilzomib treatment can leave you unusually tired or weak, especially around an infusion; tell the treatment team if it limits normal activity.
• Low red blood cells: Reduced red blood cells may cause pale skin, weakness or breathlessness; report worsening symptoms so blood counts can be checked.
• Low platelets: A reduced platelet count can cause easy bruising, nosebleeds or bleeding gums; report any unusual bleeding immediately.
• Nausea: Feeling sick can occur after treatment and may make drinking difficult; tell the healthcare team if vomiting or poor fluid intake develops.
• Fever or chills: Treatment can be followed by fever, which may also signal infection; seek prompt medical advice for fever, shaking or a new cough.

• Attend every blood test and treatment appointment.
• Tell your treatment team about fever, chills, cough or other signs of infection.
• Report unusual bruising, bleeding, chest discomfort or sudden breathlessness promptly.
• Drink fluids only as advised by your cancer specialist.
• Avoid driving if you feel dizzy, faint, sleepy or unusually tired.

Overdose

Missed a Dose

Interactions with other medicines

Interactions with food items